New pill shows promise for tough lung cancers
NCT ID NCT07374419
First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times
Summary
This study tests an experimental drug, atamparib, in 178 adults with advanced or metastatic non-small cell lung cancer (a common type of lung cancer) that has not responded to standard treatments. The trial has two parts: first, finding the safest dose, then checking how well it works. Participants take atamparib by mouth twice daily.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- atamparib (an experimental drug taken by mouth)
- What this could lead to
- If successful, this could point toward a new treatment option for people with advanced lung cancer whose disease has worsened after standard therapy.
- What could go wrong
- This is an early-phase trial (Phase Ib/II) with a small number of participants, so the drug may not prove effective or safe enough for wider use. Side effects are unknown at this stage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Unit 3.53, 3rd Floor, No. 5, Lane 720 Cailun Road, Pilot Free Trade Zone, Shanghai, P.R.China
RECRUITINGShanghai, Shanghai Municipality, 200000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a new PET tracer reveal a key cancer target?
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new tracer light up cancer growth?
- Can a Dual-Pronged antibody outsmart advanced cancers?